Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the kidney cancer diagnostics and therapeutics market?

In recent times, the market size for kidney cancer diagnostics and therapeutics has witnessed a robust growth. An escalation from $4.1 billion in 2024 to $4.32 billion in 2025, representing a compound annual growth rate (CAGR) of 5.4%, is expected. The surge in growth during the historical period can be linked to progress in molecular biology research, clinical trials, drug creation, surgical breakthroughs, revelations in genetics, and enhancements in healthcare access.

What will be the kidney cancer diagnostics and therapeutics market size in the future?

Anticipated to experience a significant surge in the coming years, the kidney cancer diagnostics and therapeutics market is projected to expand to $5.68 billion by 2029, boasting a compound annual growth rate (CAGR) of 7.0%. Various factors underpinning this predicted growth during the aforementioned period include innovations in biomarker research, advancements in genomic sequencing, the increasing use of telemedicine and remote consultations, developments in precision medicine, and the advent of rapid diagnostic technologies. Key trends anticipated throughout the forecast timeframe encompass the integration of palliative care, the amplification of long-term survivorship care, interventions in nutrition and lifestyle, the broadened role of radiomics, and the adoption of liquid biopsies.

Get your kidney cancer diagnostics and therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/kidney-cancer-diagnostics-and-therapeutics-global-market-report

What main drivers are fueling expansion in the kidney cancer diagnostics and therapeutics market?

The growth of the kidney cancer diagnostics and therapeutics market is anticipated to be spurred by the rising prevalence of kidney cancer. This form of cancer arises when abnormal changes occur in the normal cells of either one or both kidneys, causing them to grow uncontrollably and form a mass or renal cortical tumor. Diagnostics and therapeutics are pivotal in the management and treatment of kidney cancer, providing multiple advantages such as early detection, precise diagnosis, personalized medicine, and monitoring of treatment. For example, the American Society of Clinical Oncology (ASCO), a non-profit US organization dedicated to cancer care, estimated in March 2023 that kidney cancer would be diagnosed in 81,800 individuals (52,360 men and 29,440 women) in the United States in 2023. Furthermore, worldwide, kidney cancer would have imparted its effect on 431,288 individuals by 2020. Thus, the escalating prevalence of kidney cancer is anticipated to fuel the expansion of the kidney cancer diagnostics and therapeutics market.

What key areas define the segmentation of the global kidney cancer diagnostics and therapeutics market?

The kidney cancer diagnostics and therapeutics market covered in this report is segmented –

1) By Cancer Type: Clear Cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma And Transitional Cell Carcinoma, Other Cancer Types

2) By Component: Drugs, Diagnostics

3) By Diagnostics: Biopsy, CT Scan, Nephro-Ureteroscopy, Intravenous Pyelogram, Ultrasound

4) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy

5) By End-Users: Hospitals, Pharmaceutical Labs, Genomics Laboratories

Subsegments:

1) By Clear Cell RCC: Stage I, Stage II, Stage III, Stage IV

2) By Papillary RCC: Type 1, Type 2

3) By Chromophobe RCC: Localized, Advanced

4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-muscle invasive, Muscle invasive, Metastatic

5) By Other Cancer Types: Collecting Duct Carcinoma, Renal Medullary Carcinoma, Other rare types

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11937&type=smp

Who are the dominant players expanding their reach in the kidney cancer diagnostics and therapeutics market?

Major companies operating in the kidney cancer diagnostics and therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Pharmaceuticals Limited, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Siemens Healthcare GmbH, Laboratory Corporation of America Holdings, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Illumina Inc., PerkinElmer Inc., Ipsen S.A, Bio-Rad Laboratories Inc., QIAGEN NV, Exelixis Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., GeneDx LLC, CD Genomics, Genpath Life Sciences Private Limited

How are evolving market trends shaping kidney cancer diagnostics and therapeutics Strategies?

Prominent businesses in the arena of kidney cancer diagnostics and therapeutics are concentrating on creating enhanced renal cell carcinoma (RCC) methodologies to augment patient results and offer bespoke treatment solutions aligned with the unique needs of people suffering from this demanding disease. Investigations into renal cell carcinoma (RCC) are pivotal for kidney cancer diagnostics and therapeutic processes, as they facilitate the generation of pioneering diagnostic techniques and precise therapies that promote rapid diagnosis and customized care for patients. For example, Merck, a pharmaceutical organization headquartered in the US, rolled out welireg (belzutifan) in December 2023, marking the debut of the first hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor licensed for mature patients with advanced renal cell carcinoma (RCC) who have previously undergone treatments with PD-1 or PD-L1 inhibitors and VEGF-TKIs. This unique therapeutic classification exhibits substantial advantages, such as enhanced survival without progression and superior response rates relative to everolimus. The green light for WELIREG symbolizes a significant development in the kidney cancer diagnostics and therapeutics market, providing renewed optimism for patients battling the progressing disease.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11937

Which regions are emerging as leaders in the kidney cancer diagnostics and therapeutics market?

North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Skin Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Lung Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Monoclonal Antibodies (MAs) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: